Success Stories

Not all KU technology is as big a commercial success as Abilify®, but it’s a great example of how innovation, research and protecting intellectual property are helping society and funding further research at KU.

Name: Immunogenetix Therapeutics, Inc.

Immunogenetix Therapeutics, Inc. is an early stage biotechnology company developing advanced DNA-based therapies for the prevention and treatment of HIV infection. DNA-based therapies offer significant advantages over recombinant protein therapies, including an enhanced cellular immune response and long-term protection against viral diseases that require cellular immunity (e.g. HIV). The Company has exclusive worldwide rights to proprietary therapeutic candidates and supporting technologies.